About Cubist Pharmaceuticals
Cubist Pharmaceuticals is a company based in Lexington (United States) founded in 1993 was acquired by Merck in December 2014. The company has 895 employees as of December 31, 2022. Cubist Pharmaceuticals has completed 6 acquisitions, including Adolor, Calixa Therapeutics and Illumigen. Cubist Pharmaceuticals operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter Lexington, United States
- Employees 895 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cubist Pharmaceuticals, Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Cubist Pharmaceuticals
Unlock access to complete
Funding Insights of Cubist Pharmaceuticals
Detailed funding history for Cubist Pharmaceuticals
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Cubist Pharmaceuticals
Cubist Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Merck.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical products are manufactured and marketed worldwide.
|
Locked | Locked | Locked |
Investor details for Cubist Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cubist Pharmaceuticals
Cubist Pharmaceuticals has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Adolor, Calixa Therapeutics and Illumigen.
Investment portfolio details for Cubist Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Development of a novel cephalosporin against the multi-drug resistant organisms
|
Locked | Locked | 2007 | Locked | |
|
Antibiotics for serious infections are discovered, developed, and commercialized.
|
Locked | Locked | 2004 | Locked | |
|
Provider of diversified crop nutrition solutions for farmers
|
Locked | Locked | 2003 | Locked |
Complete acquisition details for Cubist Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Cubist Pharmaceuticals
Detailed financials for Cubist Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cubist Pharmaceuticals Comparisons
Peer comparison for Cubist Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cubist Pharmaceuticals
Cubist Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| Locked | Locked | Locked |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for infectious disease and inflammatory indications
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
Detailed competitors of Cubist Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cubist Pharmaceuticals
Complete news archive for Cubist Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cubist Pharmaceuticals
Cubist Pharmaceuticals was founded in 1993.
Cubist Pharmaceuticals is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Ken Frazier is the current CEO of Cubist Pharmaceuticals.
As of Dec 31, 2022, the latest employee count at Cubist Pharmaceuticals is 895.
As of Jan 2015, Cubist Pharmaceuticals operates as a subsidiary of Merck Co. Cubist Pharmaceuticals a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. It offers Cubicin (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; Dificid for the treatment of Clostridium difficile-associated diarrhea (CDAD); and Entereg (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. The company also develops Tedizolid Phosphate, a novel antibiotic product candidate for the treatment of serious gram-positive bacterial infections; and Ceftolozanetazobactam, an I.V. antibacterial product candidate for the treatment of certain serious gram-negative bacterial infections in the hospital. In addition, it develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; and Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain.
Cubist Pharmaceuticals's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Cubist Pharmaceuticals has made 6 acquisitions, including Adolor, Calixa Therapeutics, and Illumigen.
Cubist Pharmaceuticals has 1 investor. Key investors include Merck.